摘要
目的探讨阿仑膦酸钠联合注射用骨肽治疗绝经后骨质疏松患者的临床疗效以及对患者所造成的不良反应。方法选取我院2014年1月～2015年1月接收治疗的绝经后骨质疏松症患者200例，随机分成两组，各100例。其中观察组接受阿仑膦酸钠联合注射用骨肽治疗，对照组接受阿仑膦酸钠结合钙尔奇D治疗。两组疗程均为6个月。对比分析两组患者前后骨密度（BMD）、骨钙素（BGP）、碱性磷酸酶（ALP）、血钙、血磷、I型胶原羧基端肽交联（B—CTX）及不良反应发生情况。结果观察组患者治疗后L1-4、Ward’s等部位骨密度明显高于治疗前和对照组治疗后，且比较差异有统计学意义（P〈0．05）；观察组患者治疗后血清ALP、BGP水平明显低于治疗前和对照组治疗后，且比较差异有统计学意义（P〈0．05）；观察组患者治疗后B—CTX水平明显低于治疗前和对照组治疗后，且比较差异有统计学意义（P〈0．05）。结论阿仑膦酸钠联合注射用骨肽对于绝经后骨质疏松患者治疗疗效确切，能明显改善生活质量，且基本不对患者产生不良反应。
Objective To explore the clinical efficacy of alendronate combined with ossotide for injection in treatment of postmenopausal osteoporosis and the adverse reactions to patients, Methods 200 cases of patients with postmenopausal osteoporosis cured in our hospital from January 2014 to January 2015 were selected and randomly divided into two groups with 100 cases in each. Patients in observation group were treated with alendronate combined with ossotide for injection, and patients in control group were treated with alendronate combined with cahrate D. The course of treatment is 6-month long for each group. Bone mineral density （BMD）, osteocalcin （BGP）, alkaline phosphatase （ALP）, calcium, phosphorus, collagen carboxy-terminal cross-linked peptides （B-CTX） and adverse reaction conditions before and after the treatment of the two groups were compared and analyzed. Results L1 _ 4, Ward ＇s and other parts of bone mineral density after the treatment of observation group was significantly higher than that before the treatment and control group after the treatment, and the difference was statistically significant （/9 〈 0.05）. Alkaline phosphatase （ALP） and osteocalcin （BGP） after the treatment of observation group were significantly lower than that before the treatment and control group after the treatment, and the difference was statistically significant （P 〈 0.05）. Collagen carboxy-terminal cross-linked peptides （B-CTX） after the treatment of observation group were significantly lower than that before the treatment and control group after the treatment, and the difference was statistically significant （P 〈 0.05）. Conclusion The clinical efficacy of alendronate combined with ossotide for injection in treatment of postmenopausal osteoporosis is definite. It can significantly improve the quality of life. And it basically does not have adverse reactions to patients.
出处
《中国医药科学》
2016年第18期57-59,72,共4页
China Medicine And Pharmacy
关键词
阿仑膦酸钠
骨肽
绝经
骨质疏松症
疗效
不良反应
Alendronate
Ossotide
Menopause
Osteoporosis
Efficacy
Adverse reactions
